While GLP-1 analogs for treatment of type 2 diabetes cause mild-to-moderate nausea and vomiting in a significant proportion of patients, their benefits in terms of weight loss and improved glycemic control have allowed the class to overcome these tolerability concerns and become one of the most-prescribed classes of type 2 diabetes medications in the US and Europe (326). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.